Profile data is unavailable for this security.
About the company
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
- Revenue in JPY (TTM)0.00
- Net income in JPY-2.06bn
- Incorporated2016
- Employees14.00
- LocationModalis Therapeutics Corp4FY's Bldg., 16-5, Nihonbashi Kabuto-choCHUO-KU 103-0023JapanJPN
- Phone+81 368224584
- Websitehttps://www.modalistx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kringle Pharma Inc | 72.62m | -905.42m | 2.98bn | 17.00 | -- | 2.37 | -- | 40.98 | -130.95 | -130.95 | 10.48 | 170.57 | 0.032 | -- | 1.01 | 4,272,000.00 | -39.93 | -23.52 | -42.03 | -24.93 | -- | -- | -1,246.73 | -349.89 | 16.65 | -3,738.20 | 0.00 | -- | -9.77 | -31.17 | -21.13 | -- | -- | -- |
| Veritas In Silico Inc | 91.14m | -425.67m | 3.11bn | 19.00 | -- | 1.75 | -- | 34.17 | -65.62 | -65.62 | 14.05 | 274.99 | 0.0441 | -- | 6.11 | -- | -20.59 | -- | -21.32 | -- | -- | -- | -467.05 | -- | 18.35 | -- | -- | -- | -53.18 | -- | -80.03 | -- | -- | -- |
| NPT Co Ltd | 0.00 | -266.47m | 3.41bn | 7.00 | -- | 43.82 | -- | -- | -54.98 | -54.98 | 0.00 | 15.98 | 0.00 | -- | -- | 0.00 | -318.44 | -- | -439.04 | -- | -- | -- | -- | -- | -- | -2,152.88 | 0.00 | -- | -- | -- | -68.67 | -- | -- | -- |
| FunPep Co Ltd | 314.00k | -1.91bn | 3.98bn | 15.00 | -- | 2.72 | -- | 12,660.04 | -51.03 | -51.03 | 0.0083 | 36.09 | 0.0001 | -- | -- | -- | -75.09 | -37.74 | -92.91 | -41.17 | -- | -- | -608,766.90 | -4,142.72 | 3.71 | -- | -- | -- | -94.88 | -36.20 | -115.00 | -- | -- | -- |
| Human Metabolome Technologies Inc | 1.43bn | 207.06m | 4.12bn | 62.00 | 19.65 | -- | 27.54 | 2.88 | 35.42 | 35.42 | 248.83 | -- | 0.6237 | 10.29 | 4.91 | 23,060,290.00 | 9.03 | 10.54 | 10.98 | 13.59 | 60.48 | 66.65 | 14.48 | 17.24 | 5.13 | 391.35 | 0.0555 | 20.98 | 8.12 | 5.40 | 5.42 | -- | 33.68 | -- |
| Ribomic Inc | 0.00 | -1.05bn | 4.67bn | 25.00 | -- | 1.36 | -- | -- | -23.81 | -23.81 | 0.00 | 63.04 | 0.00 | -- | -- | 0.00 | -31.15 | -29.95 | -32.30 | -31.15 | -- | -- | -- | -2,725.95 | 25.20 | -- | 0.00 | -- | -- | -55.55 | 0.5173 | -- | -6.86 | -- |
| Modalis Therapeutics Corp | 0.00 | -2.06bn | 5.16bn | 14.00 | -- | 1.75 | -- | -- | -27.71 | -27.71 | 0.00 | 33.64 | 0.00 | -- | -- | 0.00 | -66.07 | -35.65 | -74.94 | -36.83 | -- | -- | -- | -1,981.18 | -- | -- | 0.0888 | -- | -- | -- | 44.90 | -- | -67.80 | -- |
| D.Western Therapeutics Institute Inc | 419.76m | -1.06bn | 5.75bn | 21.00 | -- | 3.85 | -- | 13.70 | -24.98 | -24.98 | 9.48 | 27.56 | 0.1921 | 0.4194 | 2.71 | 19,988,760.00 | -48.31 | -24.39 | -52.24 | -26.58 | 89.75 | 93.00 | -251.53 | -142.25 | 8.69 | -274.87 | 0.2606 | -- | 10.09 | -4.07 | -58.82 | -- | -- | -- |
| Carna Biosciences, Inc. | 579.06m | -2.17bn | 5.94bn | 63.00 | -- | 19.19 | -- | 10.25 | -113.62 | -113.62 | 30.30 | 16.16 | 0.2894 | 1.24 | 6.17 | -- | -108.53 | -37.21 | -120.28 | -41.98 | 67.03 | 86.49 | -375.00 | -118.28 | 6.08 | -75.55 | 0.6979 | -- | -8.99 | -12.57 | 0.3262 | -- | -33.02 | -- |
| TMS Co Ltd | 0.00 | -670.20m | 6.50bn | 18.00 | -- | 2.17 | -- | -- | -15.72 | -15.72 | 0.00 | 65.78 | 0.00 | -- | -- | 0.00 | -21.59 | -- | -22.41 | -- | -- | -- | -- | -- | 23.99 | -- | 0.00 | -- | -- | -- | 31.20 | -- | -- | -- |
| Cyfuse Biomedical KK | -100.00bn | -100.00bn | 6.83bn | 21.00 | -- | 2.30 | -- | -- | -- | -- | -- | 298.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.80 | -- | 0.3038 | -- | -10.91 | -- | -48.03 | -- | -- | -- |
| Noile-Immune Biotech Inc | 7.14m | -782.47m | 7.01bn | 25.00 | -- | 1.70 | -- | 982.06 | -18.07 | -18.07 | 0.165 | 95.16 | 0.0016 | 0.00 | 0.0668 | 285,720.00 | -17.08 | -- | -17.32 | -- | 30.00 | -- | -10,954.38 | -- | 60.62 | -- | 0.00 | -- | -97.61 | -- | 14.65 | -- | -- | -- |
| Tsubota Laboratory Inc | 973.21m | -172.89m | 7.30bn | 17.00 | -- | 5.65 | -- | 7.50 | -6.79 | -6.79 | 37.61 | 50.08 | 0.4733 | 0.6726 | 4.00 | 57,247,590.00 | -8.41 | 0.1041 | -12.17 | 0.1517 | 80.27 | 71.43 | -17.76 | 0.2216 | 2.89 | -- | 0.0586 | 0.00 | 101.49 | 25.17 | 132.08 | 132.70 | 26.42 | -- |
| PRISM BioLab Co Ltd | 677.33m | -833.70m | 7.35bn | 35.00 | -- | 2.70 | -- | 10.85 | -22.84 | -22.84 | 18.54 | 73.59 | 0.1779 | -- | 12.58 | 19,352,290.00 | -21.90 | -- | -26.79 | -- | 39.83 | -- | -123.09 | -- | -- | -- | 0.00 | -- | 121.62 | -- | 20.56 | -- | -- | -- |
| OncoTherapy Science, Inc. | 784.25m | -881.65m | 7.53bn | 47.00 | -- | 3.52 | -- | 9.61 | -2.93 | -2.93 | 2.60 | 5.68 | 0.4224 | 8.38 | 8.72 | 16,686,090.00 | -47.48 | -63.66 | -56.22 | -77.43 | 3.63 | -0.3852 | -112.42 | -184.75 | 8.13 | -832.79 | 0.0043 | -- | 22.93 | 18.86 | 36.71 | -- | -70.80 | -- |
Data as of Feb 13 2026. Currency figures normalised to Modalis Therapeutics Corp's reporting currency: Japanese Yen JPY
3.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Evolution Capital Management LLCas of 26 Jan 2026 | 3.20m | 3.81% |
| Amova Asset Management Co., Ltd.as of 22 Apr 2024 | 0.00 | 0.00% |
Data from 31 Dec 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
